Skip to main content
Molecular biology

CD38 (NADase)

The enzyme that destroys your NAD+ and accelerates aging

Definition

CD38 is a membrane glycoprotein that acts as the main NAD+-consuming enzyme (NADase) in mammalian tissues. It degrades NAD+ and its precursors (such as NMN) to generate calcium-signaling molecules. Its expression rises sharply with age —driven by chronic low-grade inflammation (inflammaging)— precisely when the cell's capacity to synthesize NAD+ is already declining. This double hit makes CD38 a central driver of the age-related fall in NAD+ and of the mitochondrial dysfunction that accompanies it.

Detailed explanation

Eduardo Chini's group at the Mayo Clinic showed in 2016 (Cell Metabolism) that CD38 "dictates" the age-related NAD+ decline through a SIRT3-dependent mechanism: CD38 knockout mice retained youthful NAD+ levels at 32 months, whereas normal mice lost roughly half.

Mechanistically, CD38 hydrolyzes both NAD+ and its precursor NMN, limiting the effectiveness of replacement therapies (NAD+ IV, NMN, NR) if the enzyme stays hyperactive. Its age-related increase is largely explained by the accumulation of CD38-positive immune cells recruited by chronic tissue inflammation.

Inhibiting CD38 preserves NAD+ and reactivates pro-longevity pathways: sirtuins, AMPK, and more efficient mitochondrial function. The flavonoid apigenin (found in parsley, chamomile, and celery) was identified by Escande et al. (2013, Diabetes) as a natural CD38 inhibitor that raises intracellular NAD+. More potent synthetic inhibitors such as 78c reverse tissue NAD+ decline and improve metabolic function in animal models of aging.

Interested in related treatments?

Generate My Protocol

LongevityMap content is for informational and educational purposes only. It does not constitute personalised medical advice. Always consult a healthcare professional before starting any treatment. Our team · Methodology